Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : India's Serum Institute plans to start vaccine production outside India - The Times

04/30/2021 | 09:11pm EDT
FILE PHOTO: Adar Poonawalla, Chief Executive Officer (CEO) of the Serum Institute of India poses for a picture at the Serum Institute of India, Pune

(Reuters) - The Serum Institute of India, which manufactures the AstraZeneca COVID-19 vaccine, is planning to start vaccine production in other countries as it struggles to meet supply commitments, its chief executive officer told The Times.

"There's going to be an announcement in the next few days," Adar Poonawalla was quoted as saying by the newspaper in an interview published on Friday.

Poonawalla said last week that the Serum Institute would be able to raise its monthly output to 100 million doses by July, later than a previous timeline of end-May. Several states in India have run out of vaccines against COVID-19.

He hoped to increase the Serum Institute's production capacity from 2.5 billion to 3 billion doses a year within six months, the Times reported, adding that he flew to London before Britain banned travellers from India eight days ago.

Coronavirus cases and deaths have surged in India as the world's second-most populous country has reported more than 300,000 new infections daily for nine consecutive days, hitting another global record of 386,452 on Friday.

The surge has led to a public health crisis and forced the government to seek oxygen, medicines and other essentials from abroad.

The nation's coronavirus cases may peak between May 3-5, according to scientists advising the government.

Some health experts said India became complacent when new cases were running at about 10,000 a day and the novel coronavirus seemed to be under control. Authorities lifted restrictions, allowing the resumption of large festivals and political rallies.

(Reporting by Kanishka Singh in Bengaluru; Editing by Daniel Wallis and Stephen Coates)

© Reuters 2021
All news about ASTRAZENECA PLC
01:31pTHE LATEST : France welcomes EU curb on AstraZeneca vaccine
12:11pSome Countries Shift Guidance on AstraZeneca Vaccine
08:27aASTRAZENECA  : REFILE-UPDATE 2-EU has not ordered AstraZeneca vaccines beyond Ju..
06:30aEU'S BRETON : EU did not renew Astrazeneca COVID-19 vaccine order for after June
05/08EU Tepid on Biden Call to Waive Intellectual Property Rights for Covid-19 Vac..
05/08ASTRAZENECA  : Sri Lanka approves Pfizer COVID vaccine for emergency use
05/08Who have provinces pegged to receive COVID-19 vaccines in the coming weeks?
05/07Correction to Impact of U.S. Support for Patent Waiver on Vaccine Makers Arti..
05/07ASTRAZENECA PHARMA INDIA  : Key EU countries rebuff Biden on sharing COVID vacci..
05/07AstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emerge..
More news
Financials (USD)
Sales 2021 30 843 M - -
Net income 2021 4 552 M - -
Net Debt 2021 11 038 M - -
P/E ratio 2021 29,7x
Yield 2021 2,64%
Capitalization 142 B 142 B -
EV / Sales 2021 4,96x
EV / Sales 2022 4,42x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Average target price 130,07 $
Last Close Price 108,20 $
Spread / Highest target 53,4%
Spread / Average Target 20,2%
Spread / Lowest Target -12,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON7.07%443 727
ROCHE HOLDING AG-1.88%289 958
PFIZER, INC.7.53%220 784
ABBVIE INC.8.03%204 279
MERCK & CO., INC.-4.14%198 539